These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37341812)

  • 1. Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.
    Brito MJ; Sequeira P; Quintas A; Silva I; Silva F; Martins C; Félix A
    Virchows Arch; 2024 Mar; 484(3):507-516. PubMed ID: 37341812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
    Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy.
    Chinn Z; Stoler MH; Mills AM
    Histopathology; 2019 Jan; 74(2):256-268. PubMed ID: 30067880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV.
    Lovane L; Tulsidás S; Carrilho C; Karlsson C
    Sci Rep; 2024 Jun; 14(1):12974. PubMed ID: 38839923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
    Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
    Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions.
    Yoshida T; Sano T; Kanuma T; Owada N; Sakurai S; Fukuda T; Nakajima T
    Cancer; 2008 Apr; 114(2):83-8. PubMed ID: 18300235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
    Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
    Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
    Paliogiannis P; Lobrano R; Bella MA; Fara A; Uras MG; Pinna MA; Tedde A; Madonia M; Zinellu A; Cossu A
    Ann Diagn Pathol; 2024 Apr; 69():152267. PubMed ID: 38266544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
    Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M
    Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
    Zhou C; Srivastava MK; Xu H; Felip E; Wakelee H; Altorki N; Reck M; Liersch R; Kryzhanivska A; Oizumi S; Tanaka H; Hamm J; McCune SL; Bennett E; Gitlitz B; McNally V; Ballinger M; McCleland M; Zou W; Das Thakur M; Novello S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37903590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.
    Hosseini MS; Shafizadeh F; Bahremani MH; Farzaneh F; Ashrafganjoei T; Arab M; Talayeh M; Jafari F; Abdshah A
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2057. PubMed ID: 38662366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
    Curley J; Conaway MR; Chinn Z; Duska L; Stoler M; Mills AM
    Mod Pathol; 2020 Jun; 33(6):1182-1192. PubMed ID: 32139873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
    Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
    Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-ligand 1 expression in carcinoma of unknown primary.
    Kim HM; Koo JS
    BMC Cancer; 2024 Jun; 24(1):689. PubMed ID: 38844907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers.
    Mezache L; Paniccia B; Nyinawabera A; Nuovo GJ
    Mod Pathol; 2015 Dec; 28(12):1594-602. PubMed ID: 26403783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
    Reddy OL; Shintaku PI; Moatamed NA
    Diagn Pathol; 2017 Jun; 12(1):45. PubMed ID: 28623908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
    de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
    Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
    Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
    BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAD2 and CDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix.
    Kim Y; Choi JW; Lee JH; Kim YS
    Int J Gynecol Pathol; 2014 Sep; 33(5):517-23. PubMed ID: 25083970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. nm23-H1 protein immunoreactivity in intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix.
    Lee CS; Gad J
    Pathol Int; 1998 Oct; 48(10):806-11. PubMed ID: 9788265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.